This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Frontiers in Cancer Immunotherapy (1)

Frontiers in Cancer Immunotherapy

Tuesday, May 14, 2019, 9:00 AM - Wednesday, May 15, 2019, 6:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

Cancer Discussion Group

The New York Academy of Sciences

 

Immuno-oncology promises a revolution in the way we treat cancer. Since the approval of the first checkpoint inhibitors in 2014, and the subsequent approval of the first cellular therapy in 2017, the field of cancer immunotherapy has exploded with numerous ongoing clinical trials. Despite great successes, emerging results suggest that monotherapies are not sufficient to treat many cancer types and it is increasingly clear that combinatorial approaches are needed to target heterogeneous tumors and improve variability in patient response.

This two-day symposium will convene leading experts in cancer immunotherapy to discuss cutting-edge findings in the broad area of combination therapies, including checkpoint inhibitors and cellular therapies. Particular emphasis will be given to the biological mechanisms underlying combination hypotheses, bispecific antibodies and other emerging modalities for delivery of combination therapies, as well as a discussion of the importance of biomarkers and effective clinical trial design.

Call for Abstracts

Abstract submissions are invited for a poster session. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Friday, March 15,2019.

Registration

Member
By 04/02/2019
$250
After 04/02/2019
$340
Nonmember Academia, Faculty, etc.
By 04/02/2019
$400
After 04/02/2019
$540
Nonmember Corporate, Other
By 04/02/2019
$475
After 04/02/2019
$640
Nonmember Not for Profit
By 04/02/2019
$400
After 04/02/2019
$540
Nonmember Student, Undergrad, Grad, Fellow
By 04/02/2019
$270
After 04/02/2019
$365
Member Student, Post-Doc, Fellow
By 04/02/2019
$220
After 04/02/2019
$300
Deadline:
171
days
left

Scientific Organizing Committee

Frontiers in Cancer Immunotherapy (1)
Chris Boshoff, MD, PhD,
Pfizer
Frontiers in Cancer Immunotherapy (1)
Renier Brentjens, MD, PhD,
Memorial Sloan Kettering Cancer Center
Frontiers in Cancer Immunotherapy (1)
Sridhar Ramaswamy, MD,
Tesaro
Frontiers in Cancer Immunotherapy (1)
George Zavoico, PhD,
B. Riley FBR
Frontiers in Cancer Immunotherapy (1)
Sara Donnelly, PhD, The New York Academy of Sciences
Frontiers in Cancer Immunotherapy (1)
Sonya Dougal, PhD, The New York Academy of Sciences

Keynote Speakers

Frontiers in Cancer Immunotherapy (1)
Jeffrey Bluestone, PhD,
University of California, San Francisco
Frontiers in Cancer Immunotherapy (1)
Jedd Wolchok, MD, PhD,
Memorial Sloan Kettering Cancer Center
Frontiers in Cancer Immunotherapy (1)
James P. Allison, PhD,
MD Anderson Cancer Center
Frontiers in Cancer Immunotherapy (1)
Philip D. Greenberg, MD,
Fred Hutchinson Cancer Research Center

Speakers

Frontiers in Cancer Immunotherapy (1)
Thomas Gajewski, MD, PhD,
The University of Chicago
Frontiers in Cancer Immunotherapy (1)
Padmanee Sharma, MD, PhD,
MD Anderson Cancer Center
Frontiers in Cancer Immunotherapy (1)
Ronald Levy, MD,
Stanford University School of Medicine
Frontiers in Cancer Immunotherapy (1)
Lisa H. Butterfield, PhD,
University of Pittsburgh
Frontiers in Cancer Immunotherapy (1)
Rachel W. Humphrey, MD,
CytomX Therapeutics
Frontiers in Cancer Immunotherapy (1)
Steven A. Rosenberg, MD, PhD,
National Cancer Institute
Frontiers in Cancer Immunotherapy (1)
Judith Varner, PhD,
University of California, San Diego School of Medicine
Frontiers in Cancer Immunotherapy (1)
Jane L. Grogan, PhD
Genentech
Frontiers in Cancer Immunotherapy (1)
Nina Bhardwaj, MD, PhD
Icahn School of Medicine at Mount Sinai
Frontiers in Cancer Immunotherapy (1)
Kristen Hege, MD
Celgene
Frontiers in Cancer Immunotherapy (1)
Daniela F. Quail, PhD,
McGill University
Frontiers in Cancer Immunotherapy (1)
Jeffrey S. Weber, MD, PhD,
NYU Langone Medical Center
Frontiers in Cancer Immunotherapy (1)
Silvia C. Formenti, MD,
Weill Cornell Medical College

Program Support